Alzinova AB (publ) announced that an in-depth analysis of data from part A of Alzinova's phase 1b study with the vaccine candidate ALZ-101 has been completed. The analysis indicates that patients with the higher antibody levels after vaccination show a positive effect on biomarkers associated with Alzheimer's disease. This analysis provides an increased understanding of ALZ-101, which is promising in Alzinova's preparations for the phase 2 study and when the company evaluates a higher dose in parallel.

Since January 2024, when Alzinova announced positive results from the primary analysis of the phase 1b study with the vaccine candidate ALZ-101 against Alzheimer's, further analyses of the study data have been conducted. In the analyses, the company has examined exploratory endpoints, such as biomarkers related to the disease, which are important as they may indicate a potential effect of the drug. The results of the new analyses indicate a positive change in biomarkers in the cerebrospinal fluid of the patients who showed high antibody levels, so-called immune responses, during part A of the study.

The change has been identified already after 16 weeks of treatment with four doses of ALZ-101. The company plans to continue to follow up and analyse the biomarkers after treatment with a higher dosein part A2 and for a longer period of timein part B of the study. The results are planned to be presented at upcoming international medical conferences.